NCT03128606 - A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2017

Primary Completion Date

February 20, 2018

Study Completion Date

February 20, 2018

Conditions

Healthy

Interventions

DRUG

GLPG3067 single dose

GLPG3067 oral suspension, single ascending doses, daily

DRUG

Placebo single dose

Placebo, oral suspension, daily

DRUG

GLPG3067 multiple dose

GLPG3067 oral suspension, multiple ascending doses, daily for 14 days

DRUG

Placebo multiple dose

Placebo, oral suspension, daily for 14 days

DRUG

GLPG3067 oral suspension

GLPG3067 oral suspension, single dose, daily

DRUG

GLPG3067 oral tablet

GLPG3067 oral tablet, single dose, daily

DRUG

GLPG3067/GLPG2222 multiple dose

GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days

DRUG

GLPG3067/GLPG2222 Placebo multiple dose

GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days

DRUG

GLPG3067/GLPG2222/GLPG2737 multiple dose

GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days

DRUG

GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose

GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days

Trial Locations (1)

Unknown

SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp